Guardant Health, INC Form 4 insider transactions
NASDAQ
Guardant Health Director Roberto Mignone converted 264 restricted stock units into common stock, increasing his direct beneficial ownership.
NASDAQ
Guardant Health Director Manuel Hidalgo Medina acquired 232 shares of common stock on December 17, 2025, through the vesting of restricted stock units.
NASDAQ
Guardant Health Director Tariq Musa sold 116 shares of common stock for $101.46 per share under a pre-arranged Rule 10b5-1 plan.
NASDAQ
Guardant Health Director Musa Tariq acquired 250 shares of common stock through the exercise of restricted stock units on December 15, 2025.
NASDAQ
Guardant Health's Chief Legal Officer, John G. Saia, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
NASDAQ
Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and a subsequent tax-related sale of company stock.
NASDAQ
Guardant Health's Chief Commercial Officer, Chris Freeman, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.
NASDAQ
Guardant Health Co-Chief Executive Officer Helmy Eltoukhy reported the sale of 90,565 shares of common stock for approximately $9.4 million.
NASDAQ
Guardant Health's Chief Medical Officer, Craig Eagle, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.
NASDAQ
Guardant Health's Chief Technology Officer, Darya Chudova, reported the pre-planned sale of 5,451 shares of common stock for approximately $104.04 per share.
NASDAQ
Guardant Health's CFO, Michael Brian Bell, reported the vesting of restricted stock units and subsequent tax withholding on December 15, 2025, under a pre-arranged plan.
NASDAQ
Guardant Health Co-CEO AmirAli Talasaz reported sales of 100,000 common shares and transfers to trusts under a 10b5-1 plan.
NASDAQ
Guardant Health's Chief Information Officer, Kumud Kalia, sold 2,000 shares of common stock for approximately $104.60 per share under a Rule 10b5-1 plan.
NASDAQ
Guardant Health Director Manuel Hidalgo Medina exercised stock options and subsequently sold a portion of the acquired common stock.
NASDAQ
Guardant Health's Chief Technology Officer, Darya Chudova, reported the sale of over 22,000 shares of common stock and a transfer of shares to a family trust.
NASDAQ
Guardant Health's Chief Commercial Officer, Chris Freeman, sold 31,252 shares of common stock for over $3.2 million on December 5, 2025, under a pre-arranged trading plan.
NASDAQ
Guardant Health's Chief Financial Officer, Michael Brian Bell, exercised stock options and subsequently sold a significant number of common shares.
NASDAQ
Guardant Health Director Ian T. Clark exercised stock options and subsequently sold a portion of his indirectly held common stock on December 5, 2025, under a Rule 10b5-1 plan.
NASDAQ
Guardant Health's Chief People Officer, Terilyn J. Monroe, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 plan.
NASDAQ
Guardant Health Director Steve Krognes converted 155 Restricted Stock Units into common stock on November 30, 2025, increasing his direct common stock holdings.
NASDAQ
Guardant Health Director Roberto Mignone acquired 264 shares of common stock through the vesting of restricted stock units.
NASDAQ
Guardant Health Director Tariq Musa sold 116 shares of common stock for $96.25 per share under a pre-arranged Rule 10b5-1 plan.
NASDAQ
Guardant Health Director Manuel Hidalgo Medina reported the vesting and conversion of 232 restricted stock units into common stock.
NASDAQ
Guardant Health Director Tariq Musa reported the vesting of 250 restricted stock units into common stock, increasing his direct ownership.
NASDAQ
Guardant Health Director Manuel Hidalgo Medina exercised stock options and subsequently sold 1,500 shares of common stock on November 7, 2025.
NASDAQ
Guardant Health's Chief Legal Officer, John G. Saia, reported a planned future sale of 8,996 shares of common stock at $96.25 per share under a Rule 10b5-1 plan.
NASDAQ
Guardant Health Director Steve Krognes converted 154 Restricted Stock Units into common stock on October 31, 2025, as part of a pre-scheduled vesting.
NASDAQ
Guardant Health Director Roberto Mignone acquired 3,167 shares of common stock through the vesting of restricted stock units.
NASDAQ
Guardant Health Director Manuel Hidalgo Medina acquired 232 shares of common stock through the vesting of Restricted Stock Units on October 17, 2025.
NASDAQ
Guardant Health Director Tariq Musa sold 116 shares of common stock for $66.95 per share on October 17, 2025, under a pre-arranged Rule 10b5-1 plan.